VEGFA and fetal growth restriction: Globally, we found a high prevalence of obstetric complications in both groups: 19.4% and 31.3% of hypertensive disorders of pregnancy, 17.7% and 12.5% of fetal lesions or fetal distress, and 9.7% and 3.1% of intrauterine growth restriction in patients treated with anti-VEGF agents or corticosteroids, respectively.